Strong growth in instrument revenue, driven by sales of the Sequel II system, was tempered by decreased consumable revenue as customers transitioned to the new platform.
In a retrospective analysis, UK researchers found that long-read sequencing of HLA genes in stem cell transplantation donors and recipients led to better outcomes.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
